1 |
J. Reiners, Jr., R. Clift & P. Mathieu. (1999). Suppression of cell cycle progression by flavonoids: dependence on the aryl hydrocarbon receptor, Carcinogenesis, 20(8), 561-1566..
|
2 |
E. Y. Choi, H. Lee, R. W. Dingle, K. B. Kim & H. I. Swanson. (2012). AHR-based Therapeutic Agents, Molecular and Cellular Pharmacology, 4(2), 53-60.
|
3 |
S. Kronenberg, C. Esser, & C. Carlberg. (2000). An aryl hydrocarbon receptor conformation acts as the functional core of nuclear dioxin signaling, Nucleic Acids Research. 28(12), 2286-2291.
DOI
|
4 |
H. T. Clarke, W. R. Kirner. (1922). Methyl Red, Organic Synthesis, 2, 47-50.
DOI
|
5 |
K. M. Burbach, A. Poland & C. A. Bradfield. (1992). Cloning of the Ah-receptor cDNA reveals a distinctive ligand-activated transcription factor, Proceedings of the National Academy of Sciences, 89(17), 8185-8189.
|
6 |
A. B. Okey, D. S. Riddick & P. A. Harper. (1994). Molecular biology of the aromatic hydrocarbon (dioxin) receptor, Trends in Pharmacological Sciences, 15(7), 226-232.
DOI
|
7 |
Ma C., Marlowe J.L., Puga A. (2009) The aryl hydrocarbon receptor at the crossroads of multiple signaling pathways. In: Luch A. (eds) Molecular, Clinical and Environmental Toxicology. Experientia Supplementum, Basel, Birkhauser. DOI : https://doi.org/10.1007/978-3-7643-8336-7_9
|
8 |
F. Yang & D. Bleich. (2004). Transcriptional regulation of cyclooxygenase-2 gene in pancreatic beta-cells, Journal of Biological Chemistry, 279(34), 35403-35411.
DOI
|
9 |
E. J. Choi, D. G. Toscano, J. A. Ryan, N. Riedel & W. A. Toscano, Jr. (1991). Dioxin induces transforming growth factor-alpha in human keratinocytes, The Journal of Biological Chemistry, 266(15), 9591-9597.
DOI
|
10 |
A. Levine-Fridman, L. Chen & C. J. Elferink. (2004). Cytochrome P4501A1 promotes G1 phase cell cycle progression by controlling aryl hydrocarbon receptor activity, Molecular Pharmacology, 65(2), 461-469.
DOI
|
11 |
J. Guo, M. Sartor, S. Karyala, M. Medvedovic, S. Kann, A. Puga, P. Ryan & C. R. Tomlinson. (2004). Expression of genes in the TGF-beta signaling pathway is significantly deregulated in smooth muscle cells from aorta of aryl hydrocarbon receptor knockout mice, Toxicology and Applied Pharmacology, 194(1), 79-89.
DOI
|
12 |
Y. F. Lu, M. Santostefano, B. D. Cunningham, M. D. (1996). Threadgill and S. Safe, Substituted flavones as aryl hydrocarbon receptor agonists and antagonists, Biochemical Pharmacology, 51(8), 1077-1087.
DOI
|
13 |
J. E. Lee & S. Safe. (2000). 3',4'-dimethoxyflavone as an aryl hydrocarbon receptor antagonist in human breast cancer cells, Toxicological Sciences, 58(2), 235-242.
DOI
|
14 |
A. Y. Berman, R. A. Metechin, M. Y. Wiesenfeld, M. K. Holz. (2017). The therapeutic potential of resvertrol: a review of clinical trials, NPJ Precision Oncology, 1(1), 35-43.
DOI
|
15 |
S. H. Kim, E. C. Henry, D. K. Kim, Y. H. Kim, K. J. Shin, M. S. Han, T. G. Lee, J. K. Kang, T. A. Gasiewicz, S. H. Ryu, P. G. Suh. (2006). Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor, Molecular Pharmacology, 69(6), 1871-1878.
DOI
|